Page 99 - CIBEREHD2016-ENG

Most relevant scientific articles
• Claria J., Stauber R.E., Coenraad M.J., Moreau R., Jalan R., Pavesi M. et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatology. 2016;64(4):1249-1264.
• Gonzalez-Rubio S., Linares C.I., Aguilar-Melero P., Rodriguez-Peralvarez M., Montero-Alvarez J.L., De la Mata M. et al. AP-1 Inhibition by SR 11302 protects human hepatoma HepG2 cells from bile acid- induced cytotoxicity by restoring the NOS-3 expression. PLoS ONE. 2016;11(8).
• Jurado-Garcia J., Garcia-Borruel M.M., Rodriguez-Peralvarez M.L., Ruiz-Cuesta P., Poyato-Gonzalez A., Barrera-Baena P. et al. Impact of MELD allocation system on waiting list and early post-liver transplant mortality. PLoS ONE. 2016;11(6).
• Rodriguez-Peralvarez M., Rico-Juri J.M., Tsochatzis E., Burra P., De la Mata M., Lerut J.. Biopsy- proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: A systematic review and critical appraisal. Transplant International. 2016.
• Castells L., Rimola A., Manzardo C., Valdivieso A., Montero J.L., Barcena R. et al. Corrigendum
to “Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study” [J Hepatol 2015;62:92-100]. Journal of Hepatology. 2016
Hightlights
In 2016, our research group has focused its efforts in developing high quality translational/ clinical research and networking, thus aligning with CIBEREHD priorities. The main actions are summarized below:
• Development of two research projects funded by the Instituto de Salud Carlos III. FIS PI11/02867
evaluates the impact of immunosupressive regimen with mTOR inhibitor in liver transplant patients with hepatocarcinoma. The preliminary results of thsi project have been presented at AEEH-EASL meetings, both in 2016 and also accepted for 2017 and in an article. FIS PI14/01469, a more recently funded research project to investigate the role of immune system in the removal of circulating tumor cells and the hepatocarcinoma recidiva. This project is on its recruitment phase.
• Collaboration in multicentre randomized trials evaluating therapeutic options for patients with advanced hepatocellular carcinoma, HCV and liver transplant: A total of 4 Phase I-II randomized clinical trials, and 6 Phase III randomized trials.
• Participation in an European clinical guideline on modifiable risk factors in liver transplantation (COMMIT guidelines to be published in “Transplantation”). Participation in the new version of the clinical guideline on Diagnosis and Treatment of Hepatocellular Carcinoma (Medicina Clínica 2016).
• Creation of an international consortium coordinated by our research group, including 3 groups from CIBEREHD, and 3 additional institutions across Europe (Royal Free Hospital London, Padova University Hospital and Cliniques Universitaires Sant Luc, leuven). The consortium aims to reassess the prognostic impact of T-cell mediated rejection in liver transplantation under current immunosuppression protocols, and has applied recently for one of the EASL registry grants 2017.
• Three new patents have been registrated.
EHD
research Groups 99